Home > Articles > Retatrutide vs semaglutide: how the molecules and trial records differ
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Status: Investigational. Retatrutide is not approved by the FDA. Semaglutide is an active ingredient in FDA-approved drugs [1]. See our approval status page for the regulatory detail.
"Retatrutide vs semaglutide" is one of the most common comparisons in obesity-drug coverage. The question sounds simple, but the two molecules are at very different points in their development. Retatrutide's evidence comes from a phase 2 programme and a phase 3 programme that is still reporting. Semaglutide is already a component of FDA-approved drugs. This page sets out what can be compared accurately and what cannot: receptor targets, development stage and trial records.
At a glance
Question | Retatrutide | Semaglutide |
|---|---|---|
Receptor targets | GIP, GLP-1 and glucagon receptors (triple agonist) [2][5] | GLP-1 receptor (single agonist) [5] |
FDA status | Investigational; "not been found safe and effective for any condition" [1] | Active ingredient in FDA-approved drugs [1] |
Can it be compounded in the U.S.? | No, according to FDA [1] | FDA addresses compounded versions separately on the same page [1] |
Phase 3 programme | TRIUMPH and TRANSCEND trials, with some results published in 2026 [7][8] | Part of FDA-approved drugs [1]; its trial programme is outside the sources cited here |
Expected FDA decision | Listed as a 2027 event in an industry pipeline summary [14] | Not applicable |
Completed head-to-head trial vs each other | None in the sources cited here | None in the sources cited here |
The molecules: one receptor versus three
Both molecules are peptides built around incretin biology, and they share one target: the GLP-1 receptor. Beyond that shared target, they differ.
Semaglutide is a GLP-1 receptor agonist. Its effects run through that single receptor pathway, which reviews link to appetite signalling, slower stomach emptying and glucose-dependent insulin release [5].
Retatrutide (LY3437943) is a single molecule designed to activate three receptors: GIP, GLP-1 and glucagon [2][5]. The phase 2 obesity paper describes it as a "triple-hormone-receptor agonist" [2]. Reviews describe the glucagon component as the distinctive element. Activating the glucagon receptor is hypothesised to raise energy expenditure and affect liver fat metabolism, and researchers are still characterising these effects [5][6].
This is why the two molecules cannot be read as "stronger and weaker versions" of the same thing. Retatrutide adds two receptor pathways that semaglutide does not engage. Each pathway brings its own questions about effects, tolerability and which outcomes to measure. One example is a phase 2a substudy that measured MRI-assessed liver fat in participants from the retatrutide obesity trial, an outcome that reflects the research interest in the glucagon component [4]. For a fuller account of the three-receptor design, see our retatrutide guide.
Development stage: investigational versus approved
The largest practical difference is regulatory status, not chemistry.
The FDA's page on unapproved GLP-1 drugs names retatrutide directly [1]:
"Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition."
The same FDA page discusses semaglutide as an active ingredient in FDA-approved drugs, and separately covers the problems FDA has identified with unapproved and compounded versions [1]. Inclusion in approved drugs means semaglutide has passed through FDA's approval process. Retatrutide has not.
On timing, a May 2026 industry pipeline summary from Prime Therapeutics lists a retatrutide FDA decision as a 2027 event [14]. That is a forecast, not a regulatory commitment. Our approval status page tracks the filing timeline.
Trial records: what each evidence base contains
Retatrutide's published and registered trials
Phase 2, obesity (NEJM, 2023). This randomized, placebo-controlled, dose-ranging trial enrolled 338 adults with obesity, or with overweight plus at least one weight-related condition, without diabetes. The largest mean weight change reported was about 24% at 48 weeks, against about 2% with placebo [2]. A commentary on these results appeared in Expert Opinion on Investigational Drugs [6].
Phase 2, type 2 diabetes (Lancet, 2023). This randomized, double-blind trial was conducted in the USA. It was placebo-controlled, also included an active comparator, and measured glycated haemoglobin and body weight [3].
TRANSCEND-T2D-1 (Lancet, 2026). A double-blind, randomized phase 3 trial in people with type 2 diabetes whose glucose was not adequately controlled with diet and exercise [7].
TRIUMPH-2 (Lancet, 2026). A double-blind, parallel-group, randomized, placebo-controlled phase 3 trial in adults with obesity and type 2 diabetes [8][10].
TRIUMPH-1, -3 and -4 (registry records). These studies enrolled different populations. TRIUMPH-1 enrolled adults with obesity or overweight without diabetes [9]. TRIUMPH-3 enrolled people with obesity and established cardiovascular disease [11]. TRIUMPH-4 enrolled people with obesity and knee osteoarthritis [12].
Is there a head-to-head trial?
None of the sources cited on this page describes a completed trial comparing retatrutide directly with semaglutide. Most TRIUMPH studies compare retatrutide with placebo. The registered phase 3 study with an active comparator is TRIUMPH-5, and it compares retatrutide with tirzepatide, not semaglutide [13]. We cover that design in retatrutide vs tirzepatide.
Why cross-trial comparison is unreliable
Retatrutide and semaglutide figures are often shown side by side. We have deliberately not reproduced semaglutide trial percentages here, because that layout invites exactly this kind of comparison. Four factors make it misleading:
Different populations. The TRIUMPH registry records show deliberately different groups: adults without diabetes, adults with type 2 diabetes, people with cardiovascular disease and people with knee osteoarthritis [9][10][11][12]. A figure from one population does not automatically transfer to another.
Different durations. The retatrutide phase 2 obesity results are reported at 48 weeks [2]. Phase 3 trials report at their own pre-specified time points, listed in each registry record [9][10]. A percentage at one time point is not equivalent to a percentage at another.
Different endpoints and estimands. Trials can analyse results as if everyone stayed on the assigned drug, or include everyone randomized regardless of discontinuation. These choices change the headline number. Our explainer on how to read a retatrutide trial walks through this.
Different eras and comparators. Placebo responses, background lifestyle support and dropout rates can all differ between trials run years apart, which shifts the numbers even when the methods look similar.
Placebo-subtracted differences within a single trial are more informative than raw percentages across trials. Even so, only a randomized head-to-head trial can show how the two molecules compare under the same conditions. The study records can be checked directly using our guide to tracking the TRIUMPH trials on ClinicalTrials.gov.
Further reading: choosing a book on trial methods
Most of the confusion in drug comparisons comes from unfamiliarity with how trials are designed and analysed. A well-chosen methods book is one of the most practical tools for reading results critically, and it stays useful long after any single headline fades. These criteria separate strong titles from weak ones:
Accuracy and currency. Look for recent editions that cover estimands, analysis of all randomized participants and handling of missing data.
Author background. Statisticians, trialists and science journalists with a track record of correcting errors tend to write the most reliable accounts.
Worked examples. Books that dissect real published trials teach more than abstract definitions.
Format and price transparency. Compare print, e-book and audio editions, and check whether a cheaper earlier edition misses newer methods.
Level. Introductory titles suit general readers. Textbooks suit readers who want to reproduce analyses themselves.
Our reading list of books about clinical trials applies these criteria to specific titles.
Affiliate placements never influence which studies we cite or how we describe them. Our full disclosures are on the About TripleReta page.
Frequently asked questions
Is there a head-to-head trial of retatrutide and semaglutide?
Not in the sources cited here. TRIUMPH trials mostly compare retatrutide with placebo [9][10][11][12]. The registered active-comparator phase 3 study, TRIUMPH-5, uses tirzepatide as the comparator [13].
Is retatrutide approved like semaglutide?
No. FDA states that retatrutide is not a component of any FDA-approved drug and cannot be used in compounding under federal law [1]. An industry pipeline summary lists a possible FDA decision in 2027 [14].
Why can't the weight-change percentages be compared directly?
The trials enrolled different populations, ran for different lengths of time and used different analysis methods [2][9][10]. Only a randomized trial testing both molecules under the same conditions can support a direct comparison.
Do the two molecules work the same way?
They share the GLP-1 receptor. Retatrutide also activates the GIP and glucagon receptors, which semaglutide does not [2][5]. Researchers are still studying what the extra receptor activity contributes [4][5].
Related on this site
Retatrutide: mechanism, trial findings and side effects explained
Is retatrutide FDA approved? Legal status and approval timeline
Retatrutide vs tirzepatide: how the trial designs and data compare
How to read a retatrutide trial: endpoints, placebo and weight change
Last updated: 20 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.